Reyedar

Reyedar is a medtech startup founded in 2019, with a mission to revolutionize the diagnostic tools in the healthcare industry. By leveraging the power of eye tracking technology and artificial intelligence, the company aims to provide fast, objective, and patient-friendly diagnostic tools for visual impairments and neurodegenerative disorders such as Glaucoma, Parkinson's Disease, and Multiple Sclerosis. Reyedar addresses the critical need for accurate detection of early symptoms, which is often challenging with current screening tests due to invasiveness, time consumption, and unreliability in certain clinical populations. The innovative algorithm developed by Reyedar extracts biomarkers from eye movements, enabling the identification of potential underlying neurological conditions and facilitating visual assessments such as "perimetry" in just 5 minutes, a process that would typically take a couple of hours. This approach combines high-speed oculography and machine learning to translate eye movement patterns into actionable medical insights, thus significantly reducing the healthcare expenditure related to misdiagnosed disorders and preventing severe deteriorations in patients due to delayed diagnosis. Reyedar's recent milestone includes securing a substantial €3.00M Venture Round investment on 05 July 2023 from prominent investors including Cottonwood Technology Fund, UNETI Ventures, NV NOM, Blue Sparrows MedTech Funds, and Pupil Labs. With its headquarter in The Netherlands, Reyedar's groundbreaking approach to medtech signifies a promising venture with the potential to make a significant impact in the healthcare and manufacturing industries. For further insights or collaboration opportunities, visit www.reyedar.com.